Management of cutaneous T cell lymphoma: new and emerging targets and treatment options. - Wikidata - wikimedia - TriplyDB

Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.

Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.

http://www.wikidata.org/entity/Q37998019

about

Personalized treatment of Sézary syndrome by targeting a novel CTLA4:CD28 fusion.Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma Genetic rearrangements result in altered gene expression and novel fusion transcripts in Sézary syndrome The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin Apoptosis Induction and Gene Expression Profile Alterations of Cutaneous T-Cell Lymphoma Cells following Their Exposure to Bortezomib and Methotrexate Bacterial toxins fuel disease progression in cutaneous T-cell lymphoma.NFκB function and regulation in cutaneous T-cell lymphoma.Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.Vorinostat downregulates CD30 and decreases brentuximab vedotin efficacy in human lymphocytes.Bcl3 regulates pro-survival and pro-inflammatory gene expression in cutaneous T-cell lymphoma.

P2860

Q27853146-FE8CA6F7-4BEE-441A-9464-1150E0E0756C Q28534761-28ED864B-CAD0-490A-9DB7-D30E3FC17B5F Q33889309-3AB0AB9C-1522-4B44-88EA-1B59A3806A17 Q35890561-BB6CD7A7-4A45-4457-8705-5DC9D831DC55 Q36255777-5E8A76F6-0843-4100-9CE6-DDAA1368B120 Q37139517-A15E1FD1-7985-4F0C-B2CE-B888CFFF6B3A Q38162229-A426C541-73E5-45AC-9326-93DF3CBFBAD5 Q38909786-6D35AE9D-E09A-4ADD-B00C-67155707FD77 Q38947524-A5601AA0-A321-4BC5-B36A-697F7C61E56B Q42004035-14786B8E-BD81-4444-BDFD-27E24FD0E571

P2860

Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.

http://www.wikidata.org/entity/Q37998019

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.

@en

Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.

@nl

type

label

Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.

@en

Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.

@nl

prefLabel

Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.

@en

Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.

@nl

P1433

Q37998019-889EC76B-73B7-4ACD-B542-D68030088D9B

P1476

Q37998019-1AE2A499-5FE1-4BF0-9A4A-F96CC81703FF

P2093

Q37998019-55D285C3-2033-484A-9394-E3CE813B8E80

Q37998019-74373B04-B3D1-4BCB-891E-A23EC8043A8E

Q37998019-A8604CA0-19C0-4608-9B9B-C65A9F67F73F

Q37998019-BE8B3260-A7A7-4B40-9F70-8FEBBEE4EC53

Q37998019-D079ECAF-8E45-4ECD-B188-BD2D4592C9F8

Q37998019-FFF8E019-D916-46AC-95B9-686EB125D6FB

P2860

Q37998019-04666F79-1833-4540-8E68-73CFD0F7BB8C

Q37998019-0476B10C-609D-47DE-BDD2-32263E45D798

Q37998019-048792E8-655C-484F-8C6F-6CCE5217F512

Q37998019-0766FE44-F942-4B68-AD6F-BD2AFDA06B5E

Q37998019-08D02CFD-EC6C-4E5B-B2BA-67EABF2BB18E

Q37998019-0A19E9B9-CF63-4426-B02D-10D8967F3C75

Q37998019-0AB6B665-1DC6-4A2A-88FB-CBEDA09E93DE

Q37998019-0BB86930-5695-4FEF-B25A-ACD3D74E783F

Q37998019-0C13EFCA-1018-456C-9F58-17A7D95CECD7

Q37998019-0CB1E1CD-845E-4AB3-8C50-354768AA951B

P304

Q37998019-9B19E1D6-229C-4DC6-B461-F5D365C72465

P31

Q37998019-F94FC76D-3489-4CB6-9A54-76EDC1A782B9

P356

Q37998019-615605EB-BBAD-46BA-970D-BCD80BF67DBF

P407

Q37998019-A595C6CD-AD54-4996-8B35-3B0CE5142E98

P478

Q37998019-A79BFA18-759D-4D93-9390-8D56227BC927

P577

Q37998019-4D372F9D-0572-469B-8132-64D897910EE3

P698

Q37998019-80DEB9E0-021D-4C93-AEBC-8766438FEC4B

P921

Q37998019-16281E0A-E778-4554-AB33-147669BC8A85

P932

Q37998019-7F150FCE-9A42-4128-A1C8-7A4F24A08234

P356

P1433

Cancer Management and Research

P1476

Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.

@en

P2093

Alison Moskowitz

http://www.w3.org/2001/XMLSchema#string

Christiane Querfeld

http://www.w3.org/2001/XMLSchema#string

Janet Y Li

http://www.w3.org/2001/XMLSchema#string

Melissa Pulitzer

http://www.w3.org/2001/XMLSchema#string

Patricia L Myskowski

http://www.w3.org/2001/XMLSchema#string

Steven Horwitz

http://www.w3.org/2001/XMLSchema#string

P2860

Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73

Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL)

A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

The fundamental role of epigenetic events in cancer

Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndrome

CTLA-4 can function as a negative regulator of T cell activation

CCR10 is expressed in cutaneous T-cell lymphoma

Gene silencing in cancer in association with promoter hypermethylation

The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B

P304

75-89

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CMAR.S9660

http://www.w3.org/2001/XMLSchema#string

P407

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22457602

http://www.w3.org/2001/XMLSchema#string

P921

P932

3308634

http://www.w3.org/2001/XMLSchema#string